Table 3.
Outcomes
| Variable | Valved (n=36) | Nonvalved (n=31) | P-value |
|---|---|---|---|
| Final BCVA ≤20/40, n (%) | 2 (6) | 1 (3) | 1.000* |
| Final BCVA ≥20/200, n (%) | 23 (66) | 26 (84) | 0.157* |
| Final logMAR BCVA, mean (SD) | 1.47 (0.81) | 1.74 (0.88) | 0.124** |
| Snellen equivalent | 20/590 | 20/1,099 | |
| Final logMAR change in BCVA, mean (SD) | −0.36 (1.00) | −0.33 (0.94) | 0.812** |
| Approximate ETDRS improvement score | +17 | +16 | |
| Single surgery success, n (%) | 30 (83) | 24 (77) | 0.555* |
| Final anatomical success, n (%) | 34 (94) | 27 (87) | 0.404* |
| Follow-up days, mean (SD) | 345.8 (204.0) | 564.5 (333.5) | 0.004** |
Notes:
*
P-value based on Fisher’s exact test of difference between proportions.
**
P-value based on Wilcoxon rank sum test of difference between medians.
Abbreviations: BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; ETDRS, Early Treatment Diabetes Retinopathy Study.